论文部分内容阅读
本研究探讨血小板糖蛋白特异性抗体在骨髓增生异常综合征(MDS)患者发病中的作用。采用改良的MAIPA法检测血浆血小板糖蛋白特异性抗体(抗GPⅡb/Ⅲa抗体和抗GPⅠb/Ⅸ抗体)。若患者的OD值大于正常OD值的均数+3倍标准差则为阳性。结果表明:MDS组总阳性率为16.67%(5/30),ITP组总阳性率为46.67%(14/30),两者之间差异有显著性(P<0.05)。结论:部分MDS患者的糖蛋白特异性抗体为阳性,这表明部分MDS患者的血小板减少与免疫因素有关;血小板糖蛋白特异性抗体所致的血小板破坏在MDS患者的血小板减少中可能具有一定作用,这为MDS患者的免疫抑制剂治疗提供了新的依据。
This study was aimed to investigate the role of platelet glycoprotein-specific antibodies in the pathogenesis of patients with myelodysplastic syndrome (MDS). Plasma platelet glycoprotein specific antibody (anti-GPⅡb / Ⅲa antibody and anti-GPⅠb / Ⅸ antibody) was detected by the modified MAIPA method. If the patient’s OD value is greater than the normal OD value of +3 times the standard deviation is positive. The results showed that the total positive rate of MDS group was 16.67% (5/30), and the total positive rate of ITP group was 46.67% (14/30). There was a significant difference between the two groups (P <0.05). CONCLUSIONS: Some glycoprotein-specific antibodies are positive in some patients with MDS, suggesting that thrombocytopenia may be associated with immune factors in some patients with MDS. Platelet glycoprotein-specific antibody-induced platelet destruction may play a role in thrombocytopenia in MDS patients, This provides a new basis for the treatment of immunosuppressive agents in patients with MDS.